Large genetic study links telomere-related polygenic risk to distinct idiopathic pulmonary fibrosis subgroups, improving ...

There seems to be a causal relationship between genetic susceptibility to idiopathic pulmonary fibrosis (IPF) and hypertension.

The ATS/ERS 2025 statement on interstitial pneumonia classification updates the 2013 statement, with insights on secondary ...

Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...

Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains on track to be initiated by ...

If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...

FDA lifts clinical hold following review of Company’s Complete Response submission. Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites. Early data suggests ...

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a DAMP protein implicated in severe, life-threatening fibrotic diseases CAL101 being investigated in Phase 2 IPF Study; enrollment ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...